Inhibitors of c-fms kinase

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C546S210000

Reexamination Certificate

active

07662837

ABSTRACT:
The invention is directed to compounds of Formula I:wherein A, X, R2and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, colon cancer, stomach cancer, hairy cell leukemia and non-small lung carcinoma; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including arthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.

REFERENCES:
patent: 5190541 (1993-03-01), Abele et al.
patent: 5944718 (1999-08-01), Austin et al.
patent: 6100254 (2000-08-01), Budde et al.
patent: 6235746 (2001-05-01), Davis et al.
patent: 6346625 (2002-02-01), Karabelas et al.
patent: 6383790 (2002-05-01), Shokat
patent: 6596746 (2003-07-01), Das et al.
patent: 6692491 (2004-02-01), Phan
patent: 7157456 (2007-01-01), Straub et al.
patent: 2005/0004112 (2005-01-01), Player et al.
patent: 2006/0100619 (2006-05-01), McClurken et al.
patent: 2006/0122181 (2006-06-01), Ikemoto et al.
patent: 2006/0189623 (2006-08-01), Illig et al.
patent: 2006/0258724 (2006-11-01), Straub et al.
patent: 98/28264 (1998-07-01), None
patent: WO 00/27820 (2000-05-01), None
patent: WO 01/47897 (2001-07-01), None
patent: WO 01/47919 (2001-07-01), None
patent: WO 02/068406 (2002-09-01), None
patent: 2004/085388 (2004-10-01), None
Vippagunta et al., Crystalline solids, 2001, Advanced Drug Delivery Reviews, 48, pp. 3 and 18.
Abdel-Magid et al, “Reductive Amination of Aldehydes and Ketones with Sodium Triacetoxyborohydride.Studies on Direct and Indirect Reductive Amination Procedures”, J Org. Chem., vol. 61 pp. 3849-3862 (1996).
Bodansky, M. et al., “The Practice of Peptide Synthesis”, Springer-Verlag, NY (1984).
Canibano, V. et al., “Mild Regioselective Halogenation of Activated Pyridines with N-Bromusuccinimide”, Synthesis, No. 14, 2175 (2001).
Iddon. B. et al., “Polyhalogenoaromatic Compounds. Part 42. C N.m.r. Spectra of Polyhalogeno-pyridines and pyrimidines”, J. Chem. Soc. Perkin Trans. 1., 1370, (1980).
Kamwakami J., et al. “A Convenient Synthesis of 4(5)-Alkylacyl-1H-imidazoles from 4(5)-Imidazolecarboxaldehyde” Synthesis, No. 5, pp. 677-680 (2003).
Kolder, C.R., et al, “Synthesis and Reactivity of 5-Chloro-2,4-Dihydrosypyridine”, x Recl. Trav. Chim. Pays-Bas; 285 (1953).
Lyon, R. , et al., “Synthesis and Evaluation of Phenyl-and Benzoylpiperazines as Potential Serotonergic Agents”, J. Med. Chem., 29: 630-4 (1986).
Modern Amination Methods: Ricci, A., Ed., Wiley-VCH: Weinheim, 2000.
Murata, K. et al., “Synthesis of Alkenylboronates via Palladium-Catalyzed Borylation of Alkenyl Triflates (or Iodindes) with Pinacolborane” Synthesis, 2000, No. 6, pp. 778-780.
Nicolai, E., et al., “New Process for the Synthesis of Imidazo[4-5-b] pyridine Derivatives as Potent Orally Active Thromboxane A2Receptor Antagonists”, J. Heterocyclic Chemistry, 31, (73) (1994).
Wustrow, et al, “Coupling of Arylboronic Acids with a Partially Reduced Pyridine Derivative” Synthesis, 993 (1991).
Loader, C., et al., “Pyrrole chemistry. XXIII. The cyanation of substituted pyrroles with chlorosulfonyl isocyanate (CSI). New syntheses of pyrrole-3-carbonitriles.”, Can. J. Chem, 59, 2673 (1981).
Major, R., et al. “1-Alkoxy-4-phenyl-4-propionoxypiperdines and Their 3-Methyl Homologs as New Analgesics”, vol. 26, pp. 1867-1847, (1961).
Gray, M., et al. “ Practical Methylation of Aryl Halides by Suzuki-Miyaura Coupling” Tetrahedron Letters, 41:6237-40 (2000).
Katritsky, et al., “para-Formylation of NitroarenesviaVicarious Nucleophilic Substitution of Hydrogen with Tris)benzotriazol-1-yl)methane” Tetrahedron Letters 37:347-50 (1996).
Lewis, et al. “Diacetoxypiperidinium Analogs of Acetylcholine”, Junal of Medicinal Chemistry, 1973, vol. 16, No. 2 pp. 156-159.
Miyaura, N., Palladium-Catalyzed Cross-Coupling Reactions of Organoboron Compound, Chem. Rev. 95-2457 (1995).
Muci, et al., “Practical Palladium Catalysts for C-N and C-O Bond Formation”, Top. Curr., Chem. 219-131-209 (2001.
Olah, et al., “Formylating Agents”, Chem. Rev. 87: 1987.
Regan. J., “Structure-Activity Relationships of the pe8α MAAAP Kinase Inhibitor 1-(5-tert-Butyl-2-p-tolyl-2H-prazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxynaphthalen-1-yl]urea (BIRB 796)”, Med. Chem. 46:4676-86 (2003) Med. Chem. 46:2837 (2003).
Stille, J.K., Angew, “The Palladium-Catalyzed Cross-Coupling Reactions of Organotin Reagents with Organic Electrophiles”, Chem. Int. Ed. Engl. 25:508024 (1986).
Jonas, Nilsson W. et al., “Solid-Phase Synthesis of Libraries Generated from a 4-Phenyl-2-carboxy-piperazine Scaffold”, J. Comb. Chem., 2001, 3, 546-553.
Moffett, Robert Bruce et al., “Antiulcer Agents. p-Aminobenzamido Aromatic Compounds”, Journal of Medicinal Chemistry, 1971, vol. 14, No. 10, pp. 963-968.
Chemcats RN 712290-43, Jan. 1, 2004.
Chemcats RN 701272-70-0, Jan. 1, 2004.
Chemcats RN 443895-82-7 Apr. 24, 2003.
Chemcats RN 93730-20-2, Nov. 28, 1988.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Inhibitors of c-fms kinase does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Inhibitors of c-fms kinase, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of c-fms kinase will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-4187997

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.